Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study

BACKGROUND: Regorafenib, a multitargeted tyrosine kinase inhibitor, proved to be active in patients with soft tissue sarcomas (STS). METHODS: We conducted an open-label, non-randomized, single-center phase II study in advanced pretreated STS patients. Patients received regorafenib 160 mg daily on da...

Descripción completa

Detalles Bibliográficos
Autores principales: Marrari, Andrea, Bertuzzi, Alexia, Bozzarelli, Silvia, Gennaro, Nicolò, Giordano, Laura, Quagliuolo, Vittorio, De Sanctis, Rita, Sala, Simona, Balzarini, Luca, Santoro, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328961/
https://www.ncbi.nlm.nih.gov/pubmed/32590747
http://dx.doi.org/10.1097/MD.0000000000020719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328961/
https://www.ncbi.nlm.nih.gov/pubmed/32590747
http://dx.doi.org/10.1097/MD.0000000000020719

Ejemplares similares